Sequenom (SQNM) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $-0.11 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.09. The company posted revenue of $27.57 million in the period, compared to analysts expectations of $27.86 million. The company’s revenue was down -27.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.
Many Wall Street Analysts have commented on Sequenom. Sequenom was Upgraded by Ladenburg Thalmann to ” Neutral” on Mar 3, 2016.
Sequenom (SQNM) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.29 and reached the intraday high at $1.3. The bulls started the profit booking and pushed the shares to intraday low of $1.245. The trading session was marked by a volume range of 6,34,490 shares exchanging hands. The 52-week high of the shares is $4.8025 and the 52-week low is $1.1. The market cap of the company stands at $153 M and there are 11,91,87,694 shares in public circulation.
In a different news, on Mar 11, 2015, William J Welch (CEO) purchased 10,000 shares at $3.65 per share price. According to the SEC, on Mar 10, 2015, Carolyn Beaver (CFO) purchased 10,000 shares at $3.60 per share price. On Mar 6, 2015, Jeffrey D Linton (Sr VP & General Counsel) purchased 10,000 shares at $3.63 per share price, according to the Form-4 filing with the securities and exchange commission.
Sequenom Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company’s diagnostic services are provided through its wholly owned subsidiary Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in and by Sequenom Laboratories as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of and reimbursement for its prenatal LDTs and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories’ test offerings in the prenatal market include MaterniT21 PLUS LDT HerediT CF LDT SensiGene RhD LDT VisibiliT LDT and Test Send-out Agreements.